Filter
18
Filtered Results: 18
Text search:
Chipungu,
C.
Featured
Recommendations
1
New Publications
6
Language
Document type
Guidelines
7
Studies & Reports
6
No document type
5
Countries / Regions
Malawi
4
South Africa
1
Authors & Publishers
Publication Years
Category
Countries
4
Clinical Guidelines
4
Pharmacy & Technologies
1
Toolboxes
HIV
14
TB
2
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ...
Retention of knowledge and application within the community one year later
Choko AT et al. Journal of the International AIDS Society 2017, 20:21610 http://www.jiasociety.org/index.php/jias/article/view/21610 | http://dx.doi.org/10.7448/IAS.20.1.21610
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati...
À l’heure où des techniques innovantes de dépistage sur le lieu de soins (POC) sont mises sur le marché, le présent rapport soumet à l’attention des gouvernements un examen des principaux aspects relatifs à leur introduction et à leur extension au sein des programmes publics nationaux. L...
ДОПОЛНЕНИЕ
СЛУГИ ТЕСТИРОВАНИЯ НА ВИЧ
ДЕКАБРЬ 2016 г.
РУКОВОДСТВО ПО
ДОПОЛНЕНИЕ К СВОДНОМУ РУКОВОДСТВУ ПО УСЛУГАМ ТЕСТИРОВАНИЯ НА ВИЧ
ДЕКАБРЬ 2016 г.
УСЛУГИ ТЕСТИРОВАНИЯ НА ВИЧ
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...
July 2018
This fourth edition of the Unitaid/WHO market and technology landscape: HIV rapid diagnostic tests for self-testing report summarizes the current HIV testing gap; the challenges facing efforts to scale up; and the potential role HIV self-testing (HIVST) could play to achieve the United...
Supplement Article
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018 www.jaids.com
Guidelines
HIV testing services
July 2015
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...
